Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells

by Selleckchem | Feb 01 2024

Using an active targeting approach of chemotherapeutics-loaded nanocarriers (NCs) with monoclonal antibodies is a potential strategy to improve the specificity of the delivery systems and reduce adverse reactions of chemotherapeutic drugs. Specific targeting of the human epidermal growth factor receptor-2 (HER-2), expressed excessively in HER-2-positive breast cancer cells, can be achieved by conjugating NCs with an anti-HER-2 monoclonal antibody. We constructed trastuzumab-conjugated chitosan iodoacetamide-coated NCs containing doxorubicin (Tras-Dox-CHI-IA-NCs) as a tumor-targeted drug delivery system, during the study. Chitosan-iodoacetamide (CHI-IA) was synthesized and utilized to prepare trastuzumab-conjugated NCs (Tras-NCs). The morphology, physicochemical properties, drug loading, drug release, and biological activities of the NCs were elucidated. The Tras-NCs were spherical, with a particle size of approximately 76 nm, and had a positive zeta potential; after incorporating the drug, the size of the Tras-NC increased. A prolonged, 24-h drug release from the NCs was achieved. The Tras-NCs exhibited high cellular accumulation and significantly higher antitumor activity against HER-2-positive breast cancer cells than the unconjugated NCs and the drug solution. Therefore, Tras-Dox-CHI-IA-NCs could be a promising nanocarrier for HER-2-positive breast cancer.

Comments:

This sounds like a comprehensive and promising study! By utilizing a targeted approach with monoclonal antibodies and nanocarriers, you've demonstrated the potential to improve drug delivery specificity and reduce adverse effects associated with chemotherapy. Trastuzumab-conjugated chitosan iodoacetamide-coated nanocarriers loaded with doxorubicin (Tras-Dox-CHI-IA-NCs) represent a targeted drug delivery system for HER-2-positive breast cancer cells.

The spherical morphology of the Tras-NCs, their particle size of approximately 76 nm, and positive zeta potential contribute to their stability and potential for targeted delivery. The increase in size after drug incorporation is expected due to drug loading. Achieving a prolonged 24-hour drug release from these nanocarriers is impressive and beneficial for sustained therapeutic effects.

The demonstrated high cellular accumulation of Tras-NCs and their superior antitumor activity against HER-2-positive breast cancer cells compared to unconjugated NCs and the drug solution highlights the efficacy and specificity of this targeted delivery system.

Your findings suggest that Tras-Dox-CHI-IA-NCs could indeed be a promising nanocarrier for the treatment of HER-2-positive breast cancer, potentially offering improved therapeutic outcomes while minimizing adverse reactions associated with chemotherapy. Further studies and clinical trials could help validate and bring this promising approach closer to clinical applications.